We don’t expect any major changes to the stock’s fair value estimate of $164 .
Low valuations and the defensive nature of the sector should enable steady returns.
Despite the stocks’ bounce, we continue to view GSK and Sanofi as undervalued.
We don’t expect any major changes to Pfizer stock’s fair value estimate of $46.55.
No major changes to our fair value estimate expected, continue to view AbbVie stock as slightly overvalued.
This episode of Dividend-Stock Deep Dive explores what effect the Inflation Reduction Act may have on drug makers.
Growth is expected to decelerate due to pressure from generic drugs and declines in COVID-19-related demand.
And the new U.S. drug policy looks manageable.
We do not expect major changes to our fair value estimate.
COVID-19 treatments drove strong results; no major changes to Pfizer stock fair value estimate.
Stock slightly overvalued, little change expected to $167 fair value price estimate.
The defensive nature and the relative safety of healthcare stocks are supporting the sector's outperformance.
We believe the favorable pricing driving the strong performance in the quarter will fade later in the year.
Robust COVID-19 product sales should buoy the next several quarters.
Likely concerns on Humira biosimilars weigh on stock.
This data and strong Q1 results support our fair value estimate increase and strengthen the firm's wide moat.
Despite headwinds from inflation, the war in Ukraine, and supply chain issues, our fair value estimate for the wide-moat drugmaker remains unchanged.
Threat of U.S. policy changes fading.
The market isn't accounting for pressures on top drug Humira.
The drugmaker offers investors robust growth and an attractive dividend, notes Morningstar's analyst.
Long-term growth concerns for the drugmaker cap our fair value estimate.
Our bearish calls on drugs from AbbVie and Pfizer put downside pressure on the firms' valuations.
We view the wide-moat company as slightly overvalued.
We think the COVID-19 treatment market will have more longevity.
We predict a significant decline in sales in 2023.
Although the company fell a little below our expectations in the fourth quarter, our fair value estimate remains.
Increased contracts for COVID-related products are just part of the reason for the upgrades.
Large biopharma names are undervalued while device and diagnostic industries look pricey.
Our analyst views this as just one of several more likely purchases for the wide-moat drug maker.
Morningstar's sector director discusses dividend growth and our favorite dividend payers in the industry.
Morningstar's analyst says there's much more to Pfizer's products than COVID-19 vaccines and treatments.
Merck’s updated analysis for its coronavirus treatment, molnupiravir, could aid Pfizer’s COVID-19 treatment, Paxlovid.
The surprise breakup will allow both new companies to operate with more focus and agility. We don't see this impacting our fair value estimate.
Our top two picks in this wide-moat industry are poised to benefit.
We don’t expect any major change to our fair value estimate or the fair values for firms with competing COVID treatments, including Merck.
We have raised our fair value estimate based on the company's strong performance.
We don't expect major changes to the firm's fair value estimate.
The wide-moat company reported a strong third quarter, but we don't expect any significant changes to our fair value estimate.
The company's overall operations are trending back toward normalization.
While the brand power of J&J has likely taken a minor hit from legal issues, this decision doesn’t affect our fair value estimate or moat rating.
Drug and biotech industries pricing in the risk of policy changes in the U.S., but we don't think there will be a big regulatory impact.
We do not expect this to significantly affect our fair value estimate or moat rating for the firm.
As we incorporate ESG factors into our analysis, we see a manageable headwind.
The warnings put pressure on key drugs for AbbVie, Pfizer, and Eli Lilly, but we don’t see any major fair value estimate impacts.
The new CEO is likely focused on continuing the industry-leading innovative strategy.
We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.
The firm's wide moat is supported by a strong portfolio and late-stage pipeline.
We believe AbbVie’s increased marketing spending on the products are helping to propel growth.
We continue to view the stock as undervalued with the market not appreciating Merck’s strong immuno-oncology position and developing pipeline, key areas that reinforce our wide moat rating.
We expect to slightly raise Pfizer’s fair value estimate based on the strong growth, but we view the stock as largely fairly valued.